Mycio Wealth Partners LLC Buys 9,324 Shares of Pfizer Inc. (NYSE:PFE)
Mycio Wealth Partners LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 19.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,662 shares of the biopharmaceutical company’s stock after acquiring an additional 9,324 shares during the period. Mycio Wealth Partners LLC’s holdings in Pfizer were worth $2,455,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Thoroughbred Financial Services LLC boosted its holdings in shares of Pfizer by 4,297.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock valued at $265,668,000 after buying an additional 2,596,269 shares in the last quarter. Marshall Wace North America L.P. boosted its holdings in shares of Pfizer by 52.9% during the 1st quarter. Marshall Wace North America L.P. now owns 7,431,974 shares of the biopharmaceutical company’s stock valued at $315,635,000 after buying an additional 2,571,626 shares in the last quarter. California Public Employees Retirement System boosted its holdings in shares of Pfizer by 14.0% during the 4th quarter. California Public Employees Retirement System now owns 20,333,138 shares of the biopharmaceutical company’s stock valued at $887,541,000 after buying an additional 2,504,336 shares in the last quarter. Railway Pension Investments Ltd bought a new stake in shares of Pfizer during the 2nd quarter valued at $10,019,000. Finally, Fisher Asset Management LLC boosted its holdings in shares of Pfizer by 3.7% during the 2nd quarter. Fisher Asset Management LLC now owns 44,133,251 shares of the biopharmaceutical company’s stock valued at $1,911,852,000 after buying an additional 1,559,405 shares in the last quarter. Institutional investors and hedge funds own 71.58% of the company’s stock.
A number of brokerages recently issued reports on PFE. Barclays reiterated a “hold” rating and issued a $41.00 price target on shares of Pfizer in a research note on Thursday, May 9th. Goldman Sachs Group reiterated a “buy” rating and issued a $49.00 price target on shares of Pfizer in a research note on Monday, June 17th. Bank of America cut shares of Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. UBS Group reiterated a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a research note on Monday, August 5th. Finally, Morgan Stanley cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $48.00 to $40.00 in a research note on Tuesday, July 30th. Fourteen analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $46.67.
NYSE:PFE traded up $0.18 during mid-day trading on Friday, reaching $35.26. The company’s stock had a trading volume of 4,121,113 shares, compared to its average volume of 35,277,908. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The firm’s fifty day moving average price is $39.79 and its two-hundred day moving average price is $41.47. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The stock has a market cap of $194.43 billion, a P/E ratio of 11.75, a PEG ratio of 2.76 and a beta of 0.63.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.8 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 4.08%. The ex-dividend date is Thursday, August 1st. Pfizer’s payout ratio is currently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.